CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Interest Expense Nonoperating
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Interest Expense Nonoperating of $30.34 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. interest expense nonoperating for the quarter ending 2026-06-27 was $30.34M, a 1.24% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. interest expense nonoperating for the quarter ending 2026-03-28 was $26.74M, a 4.10% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. interest expense nonoperating for the quarter ending 2025-12-27 was $23.77M, a 15.79% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. interest expense nonoperating for the quarter ending 2025-09-27 was $25.40M, a 16.12% decline year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. interest expense nonoperating for fiscal 2025 was $107.03M, a 15.25% decline from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. interest expense nonoperating for fiscal 2024 was $126.29M, a 7.62% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. interest expense nonoperating for fiscal 2023 was $136.71M, a 130.57% increase from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. interest expense nonoperating for fiscal 2022 was $59.29M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-27 | $30.34M 10-Q · filed 2026-08-05 | $57.08M 10-Q · filed 2026-08-05 | $80.86M derived: sum of 3 quarters · filed 2026-08-05 | $106.26M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | $26.74M 10-Q · filed 2026-05-07 | $50.52M derived: sum of 2 quarters · filed 2026-05-07 | $75.92M derived: sum of 3 quarters · filed 2026-05-07 | $105.89M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-27 | $23.77M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $49.18M derived: sum of 2 quarters · filed 2026-02-18 | $79.14M derived: sum of 3 quarters · filed 2026-08-05 | $107.03M 10-K · filed 2026-02-18 |
| 2025-09-27 | $25.40M 10-Q · filed 2025-11-05 | $55.37M derived: sum of 2 quarters · filed 2026-08-05 | $83.25M 10-Q · filed 2025-11-05 | $111.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-28 | $29.97M 10-Q · filed 2026-08-05 | $57.85M 10-Q · filed 2026-08-05 | $86.08M derived: sum of 3 quarters · filed 2026-08-05 | $116.37M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-29 | $27.88M 10-Q · filed 2026-05-07 | $56.12M derived: sum of 2 quarters · filed 2026-05-07 | $86.40M derived: sum of 3 quarters · filed 2026-05-07 | $119.17M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-28 | $28.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $58.52M derived: sum of 2 quarters · filed 2026-02-18 | $91.29M derived: sum of 3 quarters · filed 2026-02-18 | $126.29M 10-K · filed 2026-02-18 |
| 2024-09-28 | $30.28M 10-Q · filed 2025-11-05 | $63.05M derived: sum of 2 quarters · filed 2025-11-05 | $98.05M 10-Q · filed 2025-11-05 | $131.60M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-06-29 | $32.77M 10-Q · filed 2025-08-06 | $67.77M 10-Q · filed 2025-08-06 | $101.31M derived: sum of 3 quarters · filed 2026-02-18 | $135.06M derived: sum of 4 quarters · filed 2026-02-18 |
| 2024-03-30 | $35.00M 10-Q · filed 2025-05-07 | $68.55M derived: sum of 2 quarters · filed 2026-02-18 | $102.29M derived: sum of 3 quarters · filed 2026-02-18 | $137.33M derived: sum of 4 quarters · filed 2026-02-18 |
| 2023-12-30 | $33.54M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | $67.29M derived: sum of 2 quarters · filed 2026-02-18 | $102.33M derived: sum of 3 quarters · filed 2026-02-18 | $136.71M 10-K · filed 2026-02-18 |
| 2023-09-30 | $33.74M 10-Q · filed 2024-11-06 | $68.79M derived: sum of 2 quarters · filed 2024-11-06 | $103.17M 10-Q · filed 2024-11-06 | |
| 2023-07-01 | $35.04M 10-Q · filed 2024-08-07 | $69.42M 10-Q · filed 2024-08-07 | ||
| 2022-12-31 | $59.29M 10-K · filed 2025-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |